Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
about
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsIschemic Heart Disease: Special Considerations in Cardio-Oncology.Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancerCapecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreasCardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.Capecitabine: effective oral fluoropyrimidine chemotherapy.Capecitabine in carcinoma of the pancreas.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.Capecitabine-induced cardiotoxicity: case report and review of the literature.Safety of capecitabine: a review.5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.Update on cardiotoxicity of anti-cancer treatments.Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Rapidly Developing Heart Failure from Capecitabine Cardiotoxicity: A Case Study.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.
P2860
Q28087776-22BEEA15-55EC-4606-9528-1B605C9779A8Q33441165-6B806BC3-4C53-41A8-AE2F-25BC0E6A8F21Q34236097-FB3E5920-5572-4891-87A5-CF20EE96AE7DQ34306535-FDB2494B-6A6F-414B-A37E-9A845586D20BQ34449812-56ACA459-0B6E-4D6D-841B-59A1141DF5DFQ34571555-D7290D6E-2273-41FC-9174-B9E62CCB8DCEQ36164013-483CA4CB-219B-42DF-8218-241A4141DF54Q36548730-0002514C-B9A1-415E-AA6E-1784724FE646Q37038711-F0A9C0C5-EF3B-4118-961C-94FBF193E180Q37355866-190A8156-8A14-476F-97FB-101AB664C523Q37697516-983094CA-02D2-493B-97CF-5DEC5D73C4D6Q37781051-09B02D1A-3E8E-414C-9593-16E86DE21EA5Q38067509-36F9E421-B4EB-43F2-823D-F536434FF6D8Q38410725-E6AB13CE-6788-4CAD-B6DE-8F87594949A6Q38503419-42017AF5-4C86-41C7-AAA6-8900FA812679Q38686222-685EAD24-C3F0-469A-9B7C-981B43F376C1Q38817372-A471E345-A3EB-47EB-8076-C188F1F50796Q41616831-6B5FD011-1237-4435-871F-F3F18B8A9616Q43042597-AABA58C9-2890-4372-87E7-E939F11B1395Q45073135-B7D47196-B562-45DA-B3BE-E850256DEF72Q46965182-82683DBF-C1B6-4FFE-83A6-6CBAA56E7C81Q47681122-9540A5F3-CFCA-4825-A0E9-9B9B71667CC2Q48238415-1F90F9E9-1502-4E73-957F-5E22BB31FD8AQ51760757-FBB2E285-40FB-4083-988F-68A13E4308F4Q53724796-BC99F087-FF34-4BCB-8FE2-67CF86750962
P2860
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@en
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@nl
type
label
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@en
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@nl
prefLabel
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@en
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@nl
P2093
P356
P1433
P1476
Incidence of cardiotoxicity wi ...... reported with 5-fluorouracil.
@en
P2093
P304
P356
10.1093/ANNONC/MDF108
P577
2002-03-01T00:00:00Z